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INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the commonest
cancers worldwide.1 Hepatocellular carcinoma has become a
common tumor in Pakistan. This cancer is related to hepatitis
B and C virus infection in majority of the patients.2 HCC is
proven to be extremely lethal, with overall median survival
time of 1.6 months without treatment.3 The largest
concentration of the cases is found in Asia. Unfortunately,
systemic chemotherapy and radiation are ineffective. Surgical
resection has been the curative treatment in only 25-30% of
cases of HCC because of tumor extension, multiplicity and
underlying cirrhosis.4 Liver transplantation is applicable to
only a small proportion of patients. 
In these patients goal of palliative treatment is to prolong their
survival by selective injection of chemotherapeutic agents
using transarterial chemoembolization (TACE).5 Selective
chemoembolization with the use of a mixture of iodized oil
(lipiodal) and chemotherapeutic agents has been effective for
unresectable HCC with good survival rates.6 Hepatic artery
embolization, with combined chemotherapy, was developed
in Japan during early 80’s for unresectable HCC.
Such a treatment makes use of the hyper vascular nature
of HCC.9 Antineoplastic agents are directly injected into the
hepatic artery, allowing high intratumoral concentrations of
drugs and thereby reducing systemic side effects. The mixture
of chemotherapeutic agents and iodized oil is almost
completely retained in neoplastic nodules10 and can remain in
HCC tissue for a long time.11 Subsequent mechanical
embolization of the artery, feeding the neoplasm, causes
ischemic damage to the tumour12 and prolongs the duration of
the effects of chemotherapeutic agents. Transcatheter arterial
chemoembolization (TACE) adds to the proven embolization
effect, the efficacy of the stable regional delivery of high
concentration of a chemotherapeutic agent.13-16 The prognosis
of patients with HCC, though unfavorable, varies in different
countries worldwide, probably because of a different
combination of exposure to carcinogenic factors and
consequent different severity of underlying disease.17 It can
be difficult to assess the efficacy of TACE because multiple
factors have been cited in different studies as measures of
success. These factors include patient survival, imaging
response (size reduction, fraction of tumor necrosis, lipiodal
retention rate, biologic response (decrease in µ-fetoprotein
levels), quality of life, and symptomatic improvement.18
Given the short life expectancy of patients with HCC, the most
relevant of these criteria for success is patient survival.
Unfortunately, patient survival is also the most controversial
of these factors. 
This study was conducted to determine the effect on survival
after transarterial chemoembolization (TACE) in patients with
unresectable hepatocellular carcinoma (HCC). 
ORIGINAL ARTICLE
MEDIAN  SURVIVAL  TIME  OF  PATIENTS  AFTER
TRANSCATHETER  CHEMO-EMBOLIZATION  FOR
HEPATOCELLULAR  CARCINOMA
Zishan Haider, Tanveer ul Haq, Khalid Munir, M. Uzair Usman and Muhammad Azeemuddin
ABSTRACT
Objective: To determine the effect on survival after transarterial chemoembolization (TACE) in patients with unresectable
hepatocellular carcinoma (HCC). 
Design: Longitudinal cohort study.
Place and Duration of Study: Radiology Department, The Aga Khan University Hospital, Stadium Road, Karachi, from December
1997 to September 2005.    
Patients and Methods: Patients undergoing TACE procedure for HCC were prospectively followed. Fortythree patients were enrolled
from December 1997 to March 2003 in the study and subjected to chemoembolization therapy. Eight out of 43 patients were excluded
from the study, who lost to follow-up. All the patients were followed till their death. Median and mean survival were calculated. 
Results: The median survival of these 35 patients was 410 days (13.6 months), with 95% confidence interval (236 days lower bound
and 536 days upper bound). Mean survival time was 603 days (20.1 months) with 95% confidence interval (394 days lower bound and
812 days upper bound). There was significant difference in mean survival time (in days) by Child’s Pugh class (c2 = 12.384; df=2, p-
value=0.002). 
Conclusion: The study showed that TACE is an effective palliative treatment. TACE increases the median survival time.
KEY WORDS: Hepatocellular  carcinoma  (HCC).   Transarterial  chemoembolization  (TACE).   Hepatoma  median 
survival time.
Department of Radiology, The Aga Khan University Hospital, Karachi.
Correspondence: Dr. Tanveer ul Haq, Associate Professor, Radiology Department,
The Aga Khan University Hospital, Stadium Road, P.O Box 3500, Karachi, 74800. E-
mail: tanveer.haq@aku.edu
Received  August  09,  2004; accepted  March  02,  2006.
PATIENTS AND METHODS
All patients who had established unresectable hepatocellular
carcinoma (HCC), referred to Radiology Department from
December 1997 to May 2003, were included in the study. The
sampling technique was non probability convenient. HCC
was confirmed by biopsy in majority of the cases. In few cases,
TACE was done on the basis of typical radiological
appearance of HCC and raised serum alpha fetoprotein levels
above 400 micrograms/liter. A questionnaire was designed
and the previous data was collected from medical records and
radiological files. Laboratory investigations e.g. bilirubin,
albumin, prothrombin time, alpha fetoprotein and
radiological investigations e.g. CT scans, ultrasounds were
reviewed before and after TACE. The classes were registered
according to “Child Pugh classification.” All cases were
followed till demise. Only those patients were included in the
study who had undergone TACE and were followed-up. The
patients who did not come for follow-up after any TACE
sitting were excluded from the study. Pre-procedure CT scans
were essentially done to assess the vascular invasion,
extension, nature and size of tumors for follow-up
comparison. Post procedure CT scans and alpha fetoprotein
were done after six weeks of every sitting. Repeat TACE were
carried out if patient had either residual tumor vascularity,
appearance of new lesion and lack of lipiodal retention.
Repeat TACE was carried out at three months, six months or
one year interval, if required at any stage. Consent was
documented and informed prior to procedure of all patients. 
TACE were performed in the angiography suite of Radiology
Department of Aga Khan University Hospital (AKUH).
Coagulopathy was corrected by transfusion of platelets
and/or fresh frozen plasma (FFP) in patients if needed at any
stage. Puncture of the femoral artery was done under local
anesthesia. Catheterization of superior mesenteric artery,
celiac artery and selective catheterization of branches of tumor
vessels was carried out. Epirubicin (50 mg) and/or mitomycin
C (2mg/cm tumor size) were given along with lipiodal
(1cc/cm of tumor size) and gel foam. Polyvinyl alcohol
particles were also given in some patients instead of gel foam
where micro-catheter technique was used (Figure 1). Kaplan
Meier method was used to determine the value of mean and
median survival time with 95 percent confidence interval. 
RESULTS
Fortythree patients with established HCC were recruited in
the study, who were then subjected to TACE procedure.
According to the exclusion criteria, 8 out of 43 patients were
excluded from the study. There were 24 males and 11 females.
Age range was 30 - 85 years with mean age of 55.5 years. There
were 8 patients who had biopsy results available for HCC and
27 patients had typical CT scan appearance of HCC with
raised alpha fetoprotein. Six out of 35 were non A, non-B
cirrhosis whereas 27 were either hepatitis B or C positive. Two
patients have had both hepatitis B and C. 
A total of 42 lesions were treated with TACE among 35
patients. Single lesion was present in 19 patients whereas 16
patients had two or more than two lesions (multicentric
hepatomas). Sixteen patients had tumor size of less than 5 cm
and 19 patients had tumor size of more than 5 cm. Total of 63
procedure sittings were done in 35 patients. In 22 patients
there was only 1 sitting of TACE, 6 patients had 2 sittings, 5
had 3 sittings, one had 5 and another had 6 sittings of TACE. 
The median survival of these 35 patients was 410 days (13.6
months), with 95% confidence interval (236 days lower bound
and 536 days upper bound) [Figure 2]. Mean survival time
was 603 days (20.1 months) with 95% confidence interval (394
days lower bound and 812 days upper bound). There was
significant difference in mean survival time (in days) by
Child’s Pugh class (c2 = 12.384; df = 2 and p-value=0.002).
There were 12 patients who were classified as Child class A, 14
as B and 9 as C. Analysis showed a significantly longer median
survival time with p-value of 0.002 relative to the severity of
underlying disease (Child’s A> B> C) which was 936 days
(31.4 months) for Child class A, 236 days (8 months) for Child
class B and 120 days (4 months) for Child class C (Table I).
There was also difference in median survival time by tumor
size (less than 5 cm >more than 5 cm). The median survival
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Figure 1:  Selective catheterization performed with the use of a microcatheter (arrow)
during TACE procedure.
Figure 2:  Survival time  in days of patients having hepatocellular carcinoma (HCC)
after TACE.
time was 762 days (25.6 months) for the patients who had
tumor size less than 5 cm. The median survival time was 345
days (11.6 months) for tumor size more than 5cm (Table II). 
None of the patients had major complications after TACE.
Eighteen patients developed pain during and immediately
after TACE sitting and were managed accordingly. Twelve
patients complained of nausea with settlement after
conservative treatment. Eight patients had low grade fever.
One patient experienced transient alopecia.
DISCUSSION
Hepatocellular carcinoma is a common form of malignancy in
Asia. In some western countries, a high incidence rate is
frequently seen among Asian immigrants as well.3 The causal
factors in Asians are distinctly different from those in western
patients, and chronic hepatitis B and C infections are the most
common etiologies.5 The treatment for HCC remains difficult
because of the advanced tumor stage at the time of diagnosis
and concomitant cirrhosis. TACE is the most widely used
therapy in patients with HCC who are considered to be
unsuitable candidates for surgery.8
These tumors are mainly fed by hepatic artery. Injecting oil
and chemo-mixture directly into the artery has a local and
long-standing effect on the tumor and this was the rationale
for TACE. In Pakistan, TACE is a relatively new procedure.
The purpose of conducting this study was to compare median
survival time with other parts of the world and to identify
effectiveness of therapy in our settings. Several well-designed
case control and retrospective studies have convincingly
demonstrated a benefit of TACE on patients with untreated or
historical control subjects. Despite the promising findings
reported by dozens of non-randomized trials, these results
have yet to be supported by data from randomized control
trials (RCTs). Almost all RCTs, however, failed to compare
TACE patients with untreated control subjects. RCTs have
compared TACE patients with control groups treated with
hormone therapy25, radiation therapy11 , and systemic
chemotherapy.20
Comparing this study with the studies in other parts of the
world, it is worthy to consider Bronowicki et al.31 The median
survival time in this study was 18 months compared to 13.6
months of our study. The difference may be due to large
sample size of 127 patients, not including Child C patients and
use of Cisplatin. Stefanini22, et al. had a sample size of 69
patients, Child’s C patients were excluded and grouping done
for lipiodal uptake in three groups. The median survival time
in this study was 21 months, which may be due to the above
mentioned differences. Ryder21 et al. showed relatively poor
results of 9 months compared to this study. The reason may be
that majority of the patients were dropped into exclusion
criteria like patients with survival time of 10 weeks were
excluded early from the study, 2 patients were alive (3 years)
till the publishing of this study and one went for
transplantation. Furthermore, 5 patients died due to
complications during the procedure. These complications
were not seen in the reported series.
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Table I:  Child’s class and median survival time.
Child’s Pugh class/ A B C
No. of patients 12 14 9
Median survival time 936 days 236 days 120 days 
(31.2 months) (7.8 months) (4 months)
Table II:  Tumor size and median survival time.
Tumor size Median survival time
Less than 5 cm 19 patients 762 days (25.6 months)
More than 5 cm 16 patients 345 days (11.6 months)
Table III:  Western series of TACE for hepatocellular carcinoma in comparison with our study.
Median survival
Author Year Therapy Number (months) P
Prospective, randomized
Pelletier25 1990 Dox + Gel 21 4 NS
Supportive care 21 6
French group 23 1995 Cis + Lip + Gel 50 19 0.13
Supportive care 46 8
Retrospective, matched historical controls
Vetter13 1991 Dox + Lip + Gel 30 12 <0.001
Supportive care 30 3
Bronowicki 31 1994 Dox.Cis, or Epi+Lip+Gel 127 18 <0.0001
Supportive care 127 5
Stefanini22 1995 Dox + Lip + Gel 69 21 <0.001
Supportive care 64 3
Retrospective, nonmatched controls
Bronowicki 32 1996 Dox,Cis,or Epi+Lip+Gel 42 36 <0.0001
Supportive care 33 11
Stuart33 1996 Dox + Lip + Gel 137 14 <0.01
Supportive care 81 2
Marcos-Alvarez20 1996 Dox + Lip + Gel 30 13 <0.05
Supportive care 22 5
Ryder21 1996 Dox + Lip + Gel 67 9 N/A
Non-Surgical therapy 118 3
Rose 19 1998 Dox + Lip + Gel 35 9 <0.0001
Supportive care 31 3
AKUH 2005 Dox + Lip + Gel 35 13.6 <0.002
Dox = doxirubicin; Cis = cisplatin; Epi = epirubicin; Lip = lipiodol; Gel = gelatin-foam particles or powder; NS = not statistically significant; N/A = not applicable. AKUH=Aga Khan University Hospital (our
study).
Many trials have also compared various forms of
chemoembolization without including an untreated control
group.26 The true effect of TACE on survival can, therefore,
not be ascertained because many patients included in the
control groups were given some form of treatment. In
addition, the review articles that have dealt with RCTs failed
to exclude the trials in which control groups were actually
treated, similarly, confounding their analyses.27-29 To-date,
only 5 RCTs have compared some form of TACE to supportive
care.30 This study had to face a similar deficiency with respect
to the control group, due to the fact that it was not possible to
find a matched group (untreated). A similar group cannot be
randomized once the treatment is internationally accepted.
Therefore, the median survival of control group was
compared from literature which ranged from 3 months to 8
months.17-23 Okuda et al.24 has shown overall median survival
of 1.6 months. Many recent studies19-21,23,31-33 have shown a
better survival with TACE due to refinements in the technique
and more stringent selection criteria. Result of this study is
almost similar to the average results of various studies (Table
III).
Major confounding factors like size of the tumor and
underlying cirrhosis were also addressed in this study. The
outcome of patients in this study suggested that patients with
severe disease (Child’s C) had poor prognosis (120 days). If
patients with Child’s C were excluded from this study then
the median survival time would have been better, that is 586
days. With the inclusion of Child’s C patients in this study, the
results are relatively poor. However, this still offers
therapeutic possibilities to patients in advanced cirrhosis with
HCC.  TACE has generally been reported to be more effective
in small tumors less than 4 cm10,11 or 5 cm.12 In this study, it is
obvious that median survival of patients with tumors less than
5 cm size, after TACE, is significantly better than patients
having tumors more than 5 cm. 
No major complications was observed in our study. There
were some minor and mainly the so-called postembolization
syndrome i.e., pain, nausea, vomiting and fever. The systemic
effects of the chemo-agent were also negligible due to the local
accumulation, slow release and lower dosages. Procedure
tolerance of the patients was also quite good. The treatment
also had a favorable impact on the quality of life, although, we
don’t have any quantitative analysis for such an observation.
CONCLUSION
The reported series shows that TACE is an effective palliative
treatment for patients with unresectable HCC that increases
the median survival time. Severity of underlying cirrhosis and
size of the tumor are significant prognostic factors. 
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